Hoth Therapeutics, Inc. (HOTH)
NASDAQ: HOTH · Real-Time Price · USD
0.8600
+0.0094 (1.11%)
May 16, 2025, 10:19 AM - Market open
Hoth Therapeutics Employees
As of December 31, 2024, Hoth Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,172,536
Market Cap
11.33M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
HOTH News
- 4 days ago - Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers - PRNewsWire
- 4 weeks ago - Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform - PRNewsWire
- 4 weeks ago - Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial - PRNewsWire
- 6 weeks ago - Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ - PRNewsWire
- 6 weeks ago - Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours - PRNewsWire
- 6 weeks ago - Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage - PRNewsWire
- 7 weeks ago - Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - PRNewsWire
- 2 months ago - Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PRNewsWire